Medicinal chemistry of quinolines as emerging anti-inflammatory agents: An overview

Current Medicinal Chemistry

Volumn 20, Issue 35, 2013, Pages 4386-4410

  Mukherjee, S ^a   Pal, M ^a  

^a INSTITUTE OF LIFE SCIENCES   (India)

Author keywords

Anti inflammatory drugs; COX; PDE4; Quinoline; Synthesis; TACE; TRPV1

Indexed keywords

AMIDE; ANTIINFLAMMATORY AGENT; CAPSAICIN; CARBOXYLIC ACID; CYCLOOXYGENASE 2 INHIBITOR; D 4418; GSK 256066; HYDROXAMIC ACID; IBUPROFEN; L 454560; N (3,5 DICHLORO 1 OXIDO 4 PYRIDINYL) 8 METHOXY 2 TRIFLUOROMETHYL 5 QUINOLINECARBOXAMIDE; NICOTINAMIDE; PHOSPHODIESTERASE IV INHIBITOR; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; PYRIMIDINE DERIVATIVE; QUINOLINE DERIVATIVE; RESINIFERATOXIN; SCH 365351; THIAZINE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1 ANTAGONIST;

ANALGESIA; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHEMISTRY; CHRONIC INFLAMMATION; CYTOKINE RELEASE; DEVELOPMENT; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG SELECTIVITY; DRUG SYNTHESIS; EXPERIMENTAL GUINEA PIG; FERRET; HUMAN; IC 50; INFLAMMATORY DISEASE; MACACA FASCICULARIS; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PAIN; PNEUMONIA; SIDE EFFECT; SQUIRREL MONKEY; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CHEMISTRY, PHARMACEUTICAL; HUMANS; INFLAMMATION; MOLECULAR STRUCTURE; QUINOLINES;

EID: 84887917753     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/09298673113209990170     Document Type: Article

References (96)

1. Kaur, K.; Jain, M.; Reddy, R. P.; Jain, R. Quinolines and structurally related heterocycles as antimalarials. Eur. J. Med. Chem., 2010, 45(8), 3245-3264.
2. Neu, H. C. Quinolone antimicrobial agents. Annu. Rev. Med., 1992, 43, 465-486.
3. Abadi, A. H.; Hegazy, G. H.; El-Zaher, A. A. Synthesis of novel 4-substituted-7-trifluoromethylquinoline derivatives with nitric oxide releasing properties and their evaluation as analgesic and antiinflammatory agents. Bioorg. Med. Chem., 2005, 13(20), 5759-5765.
4. Manera, C.; Cascio, M. G.; Benetti, V.; Allará, M.; Tuccinardi, T.; Martinelli, A.; Saccomanni, G.; Vivoli, E.; Ghelardini, C.; Marzob, V. D.; Ferrarinia, P. L. New 1,8-naphthyridine and quinoline derivatives as CB2 selective agonists. Bioorg. Med. Chem. Lett., 2007, 17(23), 6505-6510.
5. Lloyd, J.; Ryono, D. E.; Bird, J. E.; Buote, J.; Delaney, C. L.; Dejneka, T.; Dickinson, K. E. J.; Moreland, S.; Normandin, D. E.; Skwish, S.; Spitzmiller, E. R.; Waldron, T. L. Quinoline-4-carboxylic acids as angiotensin II receptor antagonists. Bioorg. Med. Chem. Lett., 1994, 4(1), 195-200.
6. Bernotas, R. C.; Singhaus, R. R.; Kaufman, D. H.; Ullrich, J.; Fletcher III, H.; Quinet, E.; Nambi, P.; Unwalla, R.; Wilhelmsson, A.; Goos-Nilsson, A.; Farnegardh, M.; Wrobel, J. Biarylether amide quinolines as liver X receptor agonists. Bioorg. Med. Chem., 2009, 17(4), 1663-1670.
7. Solomon, V. R.; Lee, H. Quinoline as a privileged scaffold in cancer drug discovery. Curr. Med. Chem., 2011, 18(10), 1488-1508.
8. Vezmar, M.; Georges, E. Reversal of MRP-Mediated Doxorubicin Resistance with Quinoline-Based Drugs. Biochem. Pharmacol., 2000, 59(10), 1245-1252.
9. Cotran, R. S., Kumar, V., Collins, T. Robbins Pathologic Basis of Disease, 6th ed.; W. B. Saunders: Philadelphia, PA, 1999.
10. Libby, P. Atherosclerosis: the new view. Sci. Am., 2002, 286(5), 46-55.
11. Hansson, G. K.; Libby, P. The immune response in atherosclerosis: a double-edged sword. Nat. Rev. Immunol., 2006, 6(7), 508-519.
12. Houslay, M. D.; Sullivan, M.; Bolger, G. B. The multienzyme PDE4 cyclic adenosine monophosphate-specific phosphodiesterase family: intracellular targeting, regulation, and selective inhibition by compounds exerting anti-inflammatory and antidepressant actions. Adv. Pharmacol., 1998, 44, 225-342.
13. Jeon, Y. H.; Heo, Y.-S.; Kim, C. M.; Hyun, Y.-L.; Lee, T. G.; Ro, S.; Cho, J. M. Phosphodiesterase: overview of protein structures, potential therapeutic applications and recent progress in drug development. Cell. Mol. Life Sci., 2005, 62(11), 1198-1220.
14. Potter, B. V. L. In: Comprehensive Medicinal Chemistry; Hansch, C., Sammes, P. G., Taylor, J. B., Eds.; Pergamon Press: Oxford, U.K., 1990, pp. 102-128.
15. Kodimuthali, A.; Jabaris, S. S. L.; Pal, M. Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease. J. Med. Chem., 2008, 51(18), 5471-5489.
16. Wilhelm, R. S.; Fatheree, P. R.; Chin R. L. Quinolines as Type IV Phosphodiesterase Inhibitors. World Patent Application WO 9422852, October 13, 1994.
17. Macdonald, D.; Perrier, H.; Liu, S.; Laliberté, F.; Rasori, R.; Robichaud, A.; Masson, P.; Huang, Z. Hunting the emesis and efficacy targets of PDE4 inhibitors: identification of the photoaffinity probe 8-(3-azidophenyl)-6- [(4-iodo-1H-1-imidazolyl)methyl] quinoline (APIIMQ). J. Med. Chem., 2000, 43(21), 3820-3823.
18. Christensen, S. B.; Guider, A.; Forster, C. J.; Gleason, J. G.; Bender, P. E.; Karpinski, J. M.; DeWolf, W. E. Jr.; Barnette, M. S.; Underwood, D. C.; Griswold, D. E.; Cieslinski, L. B.; Burman, M.; Bochnowicz, S.; Osborn, R. R.; Manning, C. D.; Grous, M.; Hillegas, L. M.; Bartus, J. O.; Ryan, M. D.; Eggleston, D. S.; Haltiwanger, R. C.; Torphy, T. J. 1,4-Cyclohexanecarboxylates: potent and selective inhibitors of phosophodiesterase 4 for the treatment of asthma. J. Med. Chem., 1998, 41(6), 821-835.
19. Hughes, B.; Howat, D.; Lisle, H.; Holbrook, M.; James, T.; Gozzard, N.; Blease, K.; Hughes, P.; Kingaby, R.; Warrellow, G.; Alexander, R.; Head, J.; Boyd, E.; Eaton, M.; Perry, M.; Wales, M.; Smith, B.; Owens, R.; Catterall, C.; Lumb, S.; Russell, A.; Allen, R.; Merriman, M.; Bloxham, D.; Higgs, G. The inhibition of antigen-induced eosinophilia and bronchoconstriction by CDP840, a novel stereo-selective inhibitor of phosphodiesterase type 4. Br. J. Pharmacol., 1996, 118(5), 1183-1191.
20. Perry, M. J.; O'Connell, J.; Walker, C.; Crabbe, T.; Baldock, D.; Russell, A.; Lumb, S.; Huang, Z.; Howat, D.; Allen, R.; Merriman, M.; Walls, J.; Daniel, T.; Hughes, B.; Laliberte, F.; Higgs, G. A.; Owens, R. J. CDP840: a novel inhibitor of PDE-4. Cell Biochem. Biophys., 1998, 29(1-2), 113-132.
21. Timmer, W.; Leclerc, V.; Birraux, G.; Neuhauser, M.; Hatzelmann, A.; Bethke, T.; Wurst, W. The new phosphodiesterase 4 inhibitor roflumilast is efficacious in exercise-induced asthma and leads to suppression of LPS-stimulated TNF-alpha ex vivo. J. Clin. Pharmacol., 2002, 42(3), 297-303.
22. Macdonald, D.; Mastracchio, A.; Perrier, H.; Dubé, D.; Gallant, M.; Lacombe, P.; Deschênes, D.; Roy, B.; Scheigetz, J.; Bateman, K.; Li, C.; Trimble, L. A.; Day, S.; Chauret, N.; Nicoll-Griffith, D. A.; Silva, J. M.; Huang, Z.; Laliberté, F.; Liu, S.; Ethier, D.; Pon, D.; Muise, E.; Boulet, L.; Chan, C. C.; Styhler, A.; Charleson, S.; Mancini, J.; Masson, P.; Claveau, D.; Nicholson, D.; Turner, M.; Young, R. N.; Girard, Y. Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: Structure-activity relationship, optimization, and identification of a highly potent, well tolerated, PDE4 inhibitor. Bioorg. Med. Chem. Lett., 2005, 15(23), 5241-5246.
23. Huang, Z.; Dias, R.; Jones, T.; Liu, S.; Styhler, A.; Claveau, D.; Otu, F.; Ng, K.; Laliberté, F.; Zhang, L.; Goetghebeur, P.; Abraham, W. M.; Macdonald, D.; Dubé, D.; Gallant, M.; Lacombe, P.; Girard, Y.; Young, R. N.; Turner, M. J.; Nicholson, D. W.; Mancini, J. A. L-454,560, a potent and selective PDE4 inhibitor with in vivo efficacy in animal models of asthma and cognition. Biochem. Pharmacol., 2007, 73(12), 1971-1981.
24. Gallant, M.; Chauret, N.; Claveau, D.; Day, S.; Deschenes, D.; Dubé, D.; Huang, Z.; Lacombe, P.; Laliberté, F.; Lévesque, J. F.; Liu, S.; Macdonald, D.; Mancini, J.; Masson, P.; Mastracchio, A.; Nicholson, D.; Nicoll-Griffith, D. A.; Perrier, H.; Salem, M.; Styhler, A.; Young, R. N.; Girard, Y. Design, synthesis, and biological evaluation of 8-biarylquinolines: a novel class of PDE4 inhibitors. Bioorg. Med. Chem. Lett., 2008, 18(4), 1407-1412.
25. Lacombe, P.; Deschênes, D.; Dubé, D.; Dubé, L.; Gallant, M.; Macdonald, D.; Mastracchio, A.; Perrier, H.; Charleson, S.; Huang, Z.; Laliberté, F.; Liu, S.; Mancini, J. A.; Masson, P.; Salem, M.; Styhler, A.; Girard, Y. Nitrogen-bridged substituted 8-arylquinolines as potent PDE IV inhibitors. Bioorg. Med. Chem. Lett., 2006, 16(10), 2608-2612.
26. Buckley, G. M.; Cooper, N.; Dyke, H. J.; Galleway, F. P.; Gowers, L.; Haughan, A. F.; Kendall, H. J.; Lowe, C.; Maxey, R.; Montana, J. G. ; Naylor, R.; Oxford, J.; Peake, J. C.; Picken, C. L.; Runcie, K. A.; Sabin, V.; Sharpea, A.; Warneck, J. B. H. 8-Methoxyquinoline-5-carboxamides as PDE4 Inhibitors: A Potential Treatment for Asthma. Bioorg. Med. Chem. Lett., 2002, 12(12), 1613-1615.
27. Billah, M.; Buckley, G. M.; Cooper, N.; Dyke, H. J.; Egan, R.; Ganguly, A.; Gowers, L.; Haughan, A. F.; Kendall, H. J.; Lowe, C.; Minnicozzi, M.; Montana, J. G.; Oxford, J.; Peake, J. C.; Picken, C. L.; Piwinski, J. J.; Naylor, R.; Sabin, V.; Shih, N.-Y.; Warneck, J. B. H. 8-Methoxyquinolines as PDE4 inhibitors. Bioorg. Med. Chem. Lett., 2002, 12(12), 1617-1619.
28. Billah, M.; Cooper, N.; Cuss, F.; Davenport, R. J.; Dyke, H. J.; Egan, R.; Ganguly, A.; Gowers, L.; Hannah, D. R.; Haughan, A. F.; Kendall, H. J.; Lowe, C.; Minnicozzi, M.; Montana, J. G.; Naylor, R.; Oxford, J.; Peake, J. C.; Piwinski, J. J.; Runcie, K. A.; Sabin, V.; Sharpe, A.; Shih, N.-Y.; Warneck, J. B. H. Synthesis and profile of SCH351591, a novel PDE4 inhibitor. Bioorg. Med. Chem. Lett., 2002, 12(12), 1621-1623.
29. Kuang, R.; Shue, H.-J.; Blythin, D. J.; Shih, N.-Y.; Gu, D.; Chen, X.; Schwerdt, J.; Lin, L.; Ting, P. C.; Zhu, X.; Aslanian, R.; Piwinski, J. J.; Xiao, L.; Prelusky, D.; Wu, P.; Zhang, J.; Zhang, X.; Celly, C. S.; Minnicozzi, M.; Billahd, M.; Wangd, P. Discovery of a highly potent series of oxazole-based phosphodiesterase 4 inhibitors. Bioorg. Med. Chem. Lett., 2007, 17(18), 5150-5154.
30. Kuang, R.; Shue, H.-J.; Xiao, L.; Blythin, D. J.; Shih, N.-Y.; Chen, X.; Gu, D.; Schwerdt, J.; Lin, L.; Ting, P. C.; Cao, J.; Aslanian, R.; Piwinski, J. J.; Prelusky, D.; Wud, P.; Zhang, J.; Zhang, X.; Celly, C. S.; Billah, M.; Wang, P. Discovery of oxazole-based PDE4 inhibitors with picomolar potency. Bioorg. Med. Chem. Lett., 2012, 22(7), 2594-2597.
31. Lunniss, C. J.; Cooper, A. W. J.; Eldred, C. D.; Kranz, M.; Lindvall, M.; Lucas, F. S.; Neu, M.; Preston, A. G. S.; Ranshaw, L. E.; Redgrave, A. J.; Robinson, J. E.; Shipley, T. J. Solanke, Y. E.; Somers, D. O.; Wiseman, J. O. Quinolines as a novel structural class of potent and selective PDE4 inhibitors: Optimisation for oral administration. Bioorg. Med. Chem. Lett., 2009, 19(5), 1380-1385.
32. Woodrow, M. D.; Ballantine, S. P.; Barker, M. D.; Clarke, B. J.; Dawson, J.; Dean, T. W.; Delves, C. J.; Evans, B.; Gough, S. L. Guntrip, S. B.; Holman, S.; Holmes, D. S.; Kranz, M.; Lindvaal, M. K.; Lucas, F. S.; Neu, M.; Ranshaw, L. E.; Solanke, Y. E.; Somers, D. O.; Ward, P.; Wiseman, J.O. Quinolines as a novel structural class of potent and selective PDE4 inhibitors. Optimisation for inhaled administration. Bioorg. Med. Chem. Lett., 2009, 19(17), 5261-5265.
33. Tralau-Stewart, C. J.; Williamson, R. A.; Nials, A. T.; Gascoigne, M.; Dawson, J.; Hart, G. J.; Angell, A. D. R.; Solanke, Y. E.; Lucas, F. S.; Wiseman, J.; Ward, P.; Ranshaw, L. E.; Knowles, R. G. GSK256066, an exceptionally high-affinity and selective inhibitor of phosphodiesterase 4 suitable for administration by inhalation: In vitro, kinetic, and in vivo characterization. J. Pharmacol. Exp. Ther., 2011, 337(1), 145-154.
34. Kumar, K. S.; Kumar, S. K.; Yogi Sreenivas, B.; Gorja, D. R.; Kapavarapu, R.; Rambabu, D.; Krishna, G. R.; Reddy, C. M.; Rao, M. V. B.; Parsa, K. V. L.; Pal, M. C-C bond formation at C-2 of a quinoline ring: Synthesis of 2-(1H-indol-3-yl) quinoline-3-carbonitrile derivatives as a new class of PDE4 inhibitors. Bioorg. Med. Chem., 2012, 20(7), 2199-2207.
35. Pal, S.; Durgadas, S.; Nallapati, S.; Mukkanti, K.; Kapavarapu, R.; Meda, C. L. T.; Parsa, K. V. L.; Pal, M. Novel 1-alkynyl substituted 1,2-dihydroquinoline derivatives from nimesulide (and their 2-oxo analogues): A new strategy to identify inhibitors of PDE4B. Bioorg. Med. Chem. Lett., 2011, 21(21), 6573-6576.
36. Durgadas, S.; Chatare, V. K.; Mukkanti, K.; Pal, S. Ceric ammonium nitrate: An efficient catalyst for one-pot synthesis of 2,2,4-trimethyl-1,2- dihydroquinolines. Lett. Org. Chem. 2010, 7(4), 306-310.
37. Caterina, M. J.; Julius, D. The vanilloid receptor: a molecular gateway to the pain pathway. Annu. Rev. Neurosci., 2001, 24, 487-517.
38. Hudson, L. J.; Bevan, S.; Wotherspoon, G.; Gentry, C.; Fox, A.; Winter, J. VR1 protein expression increases in undamaged DRG neurons after partial nerve injury. Eur. J. Neurosci., 2001, 13(11), 2105-2114.
39. Ji, R. R.; Samad, T. A.; Jin, S. X.; Schmoll, R.; Woolf, C. J. p38 MAPK activation by NGF in primary sensory neurons after inflammation increases TRPV1 levels and maintains heat hyperalgesia. Neuron, 2002, 36(1), 57-68.
40. Davis, J. B.; Gray, J.; Gunthorpe, M. J.; Hatcher, J. P.; Davey, P. T.; Overend, P.; Harries, M. H.; Latcham, J.; Clapham, C.; Atkinson, K.; Hughes, S.A.; Rance, K.; Grau, E.; Harper, A. J.; Pugh, P. L.; Rogers, D. C.; Bingham, S.; Randall, A.; Sheardown, S. A. Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia. Nature, 2000, 405(6783), 183-187.
41. Caterina, M. J.; Leffler, A.; Malmberg, A. B.; Martin, W. J.; Trafton, J., Petersen-Zeitz K. R.; Koltzenburg, M.; Basbaum, A. I.; Julius, D. Impaired nociception and pain sensation in mice lacking the capsaicin receptor. Science, 2000, 288(5464), 306-313.
42. Pal, M.; Angaru, S.; Kodimuthali, A.; Dhingra, N. Vanilloid Receptor Antagonists: Emerging Class of Novel Anti-Inflammatory Agents for Pain Management. Curr. Pharm. Des., 2009, 15(9), 1008-1026.
43. Doherty, E. M.; Fotsch, C.; Bo, Y.; Chakrabarti, P. P.; Chen, N.; Gavva, N.; Han, N.; Kelly, M. G.; Kincaid, J.; Klionsky, L.; Liu, Q.; Ognyanov, V. I.; Tamir, R.; Wang, X.; Zhu, J.; Norman, M. H.; Treanor J. J. S. Discovery of Potent, Orally Available Vanilloid Receptor-1 Antagonists. Structure-Activity Relationship of N-Aryl Cinnamides. J. Med. Chem., 2005, 48(1), 71-90.
44. Norman M. H.; Fotsch, C.; Doherty, E. M.; Bo, Y.; Chen, N.; Chakrabarti, P.; Doherty, E. M.; Gavva, N. R.; Nishimura, N.; Nixey, T.; Ognyanov, V. I.; Rzasa, R. M.; Stec, M.; Surapaneni, S.; Tamir, R.; Viswanadhan, V. N.; Treanor, J. J. Novel vanilloid receptor-1 antagonists: 1. Conformationally restricted analogues of trans-cinnamides. J. Med. Chem., 2007, 50(15), 3497-3514.
45. Doherty, E. M.; Fotsch, C.; Bannon, A. W.; Bo, Y.; Chen, N.; Dominguez, C.; Falsey, J.; Gavva, N. R.; Katon, J.; Nixey, T.; Ognyanov, V. I.; Pettus, L.; Rzasa, R. M.; Stec, M.; Surapaneni, S.; Tamir, R.; Zhu, J.; Treanor, J. J. S.; Norman, M. H. Novel Vanilloid Receptor-1 Antagonists: 2. Structure-Activity Relationships of 4-oxopyrimidines leading to the selection of a clinical candidate. J. Med. Chem., 2007, 50(15), 3515-3527.
46. Westaway, S. M.; Chung, Y.-K.; Davis, J. B.; Holland, V.; Jerman, J. C.; Medhurst, S. J.; Rami, H. K.; Stemp, G.; Stevens, A. J.; Thompson, M.; Winbornb, K. Y.; Wright, J. Ntetrahydroquinolinyl, N-quinolinyl and N-isoquinolinyl biaryl carboxamides as antagonists of TRPV1. Bioorg. Med. Chem. Lett., 2006, 16(17), 4533-4536.
47. Blum, C. A.; Caldwell, T.; Zheng, X.; Bakthavatchalam, R.; Capitosti, S.; Brielmann, H. Lombaert, S. D.; Kershaw, M. T.; Matson, D.; Krause, J. E.; Cortright, D.; Crandall, M.; Martin, W. J.; Murphy, B. A.; Boyce, S.; Jones, A. B.; Mason, G.; Rycroft, W.; Perrett, H.; Conley, R.; Burnaby-Davies, N.; Chenard, B. L.; Hodgetts, K. J. Discovery of Novel 6,6-Heterocycles as Transient Receptor Potential Vanilloid (TRPV1) Antagonists. J. Med. Chem., 2010, 53(8), 3330-3348.
48. Schmidt, R. G.; Bayburt, E. K.; Latshaw, S. P.; Koenig, J. R.; Daanen, J. F.; McDonald, H. A.; Bianchi, B. R.; Zhong, C.; Joshi, S.; Honore, P.; Marsh, K. C.; Lee, C.-H.; Faltynek, C. R.; Gomtsyan, A. Chroman and tetrahydroquinoline ureas as potent TRPV1 antagonists. Bioorg. Med. Chem. Lett., 2011, 21(5), 1338-1341.
49. Saku, O.; Ishida, H.; Atsumi, E.; Sugimoto, Y.; Kodaira, H.; Kato, Y.; Shirakura, S.; Nakasato, Y. Discovery of novel 5,5-diarylpentadienamides as orally available transient receptor potential vanilloid 1 (TRPV1) antagonists. J. Med. Chem., 2012, 55(7), 3436-3451.
50. Tracey, K. J.; Cerami, A. Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. Annu. Rev. Med., 1994, 45, 491-503.
51. Goldfeld, A. E.; Strominger, J. L.; Doyle, C. Human Tumor Necrosis Factor Gene Regulation in Phorbol Ester Stimulated T and B Cell Lines. J. Exp. Med., 1991, 174(1), 73-81.
52. Killar, L.; White, J.; Black, R.; Peschon, J. Adamalysins. A family of metzincins including TNF-alpha converting enzyme (TACE). Ann. NY Acad. Sci. 1999, 878, 442-452.
53. Kriegler, M.; Perez, C.; Defay, K.; Albert, I.; Lu, S. D. A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: Ramifications for the complex physiology of TNF. Cell, 1988, 53(1), 45-53.
54. Black, R. A.; Rauch, C. T.; Kozlosky, C. J.; Peschon, J. J.; Slack, J. L.; Wolfson, M. R.; Castner, B. J.; Stocking, K. L.; Reddy, P.; Srinivasan, S.; Melson, N.; Bioiani, N.; Schooley, K. A.; Gerhart, M.; Davis, R.; Fitzner, J. N.; Johnson, R. S.; Paxton, R. J.; March, C. J.; Cerretti, D. P. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature, 1997, 385(6618), 729-733.
55. Moss, M. L.; Jin, S.-L.; Milla, M. E.; Bickett, D. M.; Burkhart, W.; Carter, H. L.; Chem, W. J.; Clay, W. C.; Didsbury, J. R.; Hassler, D.; Hoffman, C. R.; Kost, T. A.; Lambert, M. H.; Leesnitzer, M. A.; McCauley, P.; McGeehan, F.; Mitchell, J.; Moyer, M.; Pahel, G.; Rocque, W.; Overton, L. K.; Schoenen, R.; Seaton, T.; Su, J. L.; Becherer, J. D. Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature, 1997, 385(6618), 733-736.
56. Newton, R. C.; Solomon, K. A.; Covington, M. B.; Deccico, C. P.; Haley, P. J.; Friedeman, S. M.; Vaddi, K. Biology of TACE inhibition. Ann. Rheum. Dis., 2001, 60, iii25-iii32.
57. Brown, P. D. Ongoing trials with matrix metalloproteinase inhibitors. Exp. Opin. Invest. Drugs, 2000, 9(9), 2167-2177.
58. Shaw, T.; Nixon, J. S.; Bottomley, K. M. Metalloproteinase inhibitors: new opportunities for the treatment of rheumatoid arthritis and osteoarthritis. Exp. Opin. Invest. Drugs, 2000, 9(7), 1469-1478.
59. Elliot, S.; Cawston, T. The clinical potential of matrix metalloproteinase inhibitors in the rheumatic disorders. Drugs Aging, 2001, 18(2), 87-99.
60. Aranapakam, V.; Davis, J. M.; Grosu, G. T.; Baker, J.; Ellingboe, J.; Zask, A.; Levin, J. I.; Sandanayaka, V. P.; Du, M.; Skotnicki, J. S.; DiJoseph, J. F.; Sung, A.; Sharr, M. A.; Killar, L. M.; Walter, T.; Jin, G.; Cowling, R.; Tillett, J.; Zhao, W.; McDevitt, J.; Xu, Z. B. Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis. J. Med. Chem., 2003, 46(12), 2376-2396.
61. Yocum, S. A.; Lopresti-Morrow, L. L.; Reeves, L. M.; Mitchell, P. G. In: Inhibition of Matrix Metalloproteinases: Therapeutic Applications; Greenwald, R. A., Zucker, S., Golub, L. M., Eds.; The New York Academy of Sciences: NY, 1999, pp. 583-586.
62. Moss, M. L.; White, J. M.; Lambert, M. H.; Andrews, R. C. TACE and other ADAM proteases as targets for drug discovery. Drug Discov. Today, 2001, 6(8), 417-426.
63. Duan, J. J.-W.; Chen, L.; Wasserman, Z. R.; Lu, Z.; Liu, R.-Q.; Covington, M. B.; Qian, M.; Hardman, K. D.; Magolda, R. L.; Newton, R. C.; Christ, D.D.; Wexler, R. R.; Decicco, C. P. Discovery of-Lactam Hydroxamic Acids as Selective Inhibitors of Tumor Necrosis Factor Converting Enzyme: Design, Synthesis, and Structure-Activity Relationships. J. Med. Chem., 2002, 45(23), 4954-4957.
64. Duan, J. J.-W.; Lu, Z.; Wasserman, Z. R.; Liu, R.-Q.; Covington, M. B.; Decicco, C. P. Non-hydroxamate 5-phenylpyrimidine-2,4,6-trione derivatives as selective inhibitors of tumor necrosis factor-converting enzyme. Bioorg. Med. Chem. Lett., 2005, 15(12), 2970-2973.
65. Duan, J. J.-W.; Chen, L.; Lu, Z.; Jiang, B.; Asakawa, N.; Sheppeck, J. E.; Liu, R.-Q.; Covington, M. B.; Pitts, W.; Kim, S.-H.; Decicco, C. P. Discovery of low nanomolar non-hydroxamate inhibitors of tumor necrosis factor-converting enzyme (TACE). Bioorg. Med. Chem. Lett., 2007, 17(1), 266-271.
66. Gilmore, J. L.; King, B. W.; Harris, C.; Maduskuie, T.; Mercer, S. E.; Liu, R.-Q.; Covington, M. B.; Qian, M.; Ribadeneria, M. D.; Vaddi, K.; Trzaskos, J. M.; Newton, R. C.; Decicco, C. P.; Duan, J. J.-W. Synthesis and structure-activity relationship of a novel, achiral series of TNF-converting enzyme inhibitors. Bioorg. Med. Chem. Lett., 2006, 16(10), 2699-2704.
67. Duan, J. J.-W.; Chen, L.; Lu, Z.; Xue, C.-B.; Liu, R.-Q.; Covington, M. B.; Qian, M.; Wasserman, Z. R.; Vaddi, K.; Christ, D. D.; Trzaskos, J. M.; Newton, R. C.; Decicco, C. P. Discovery of-benzamido hydroxamic acids as potent, selective, and orally bioavailable TACE inhibitors. Bioorg. Med. Chem. Lett., 2008, 18(1), 241-246.
68. Ott, G. R.; Asakawa, N.; Lu, Z.; Liu, R.-Q.; Covington, M. B.; Vaddi, K.; Qian, M.; Newton, R. C.; Christ, D. D.; Traskos, J.M.; Decicco, C. P.; Duan, J. J.-W. Cyclic-benzamido hydroxamic acids: Novel templates for the design, synthesis, and evaluation of selective inhibitors of TNF-converting enzyme (TACE). Bioorg. Med. Chem. Lett., 2008, 18(2), 694-699.
69. Ott, G. R.; Asakawa, N.; Liu, R.-Q.; Covington, M. B.; Qian, M.; Vaddi, K.; Newton, R. C.; Trzaskos, J. M.; Christ, D. D.; Galya, L.; Scholz, T.; Marshall, W.; Duan, J. J.-W. Cyclic-benzamido hydroxamic acids: Novel oxaspiro[4.4]nonane templates for the discovery of potent, selective, orally bioavailable inhibitors of tumor necrosis factor-converting enzyme (TACE). Bioorg. Med. Chem. Lett., 2008, 18(4), 1288-1292.
70. Gilmore, J. L.; King, B. W.; Asakawa, N.; Harrison, K.; Tebben, A.; Sheppeck II, J. E.; Liu, R.-Q.; Covington, M.; Duan, J. J.-W. Synthesis and structure-activity relationship of a novel, nonhydroxamate series of TNF-converting enzyme inhibitors. Bioorg. Med. Chem. Lett., 2007, 17(16), 4678-4682.
71. Mazzola Jr. R. D.; Zhu, Z.; Sinning, L.; McKittrick, B.; Lavey, B.; Spitler, J.; Kozlowski, J.; Neng-Yang, S.; Zhou, G.; Guo, Z.; Orth, P.; Madison, V.; Sun, J.; Lundell, D.; Niu, X. Discovery of novel hydroxamates as highly potent tumor necrosis factor-converting enzyme inhibitors. Part II: Optimization of the S3' pocket. Bioorg. Med. Chem. Lett., 2008, 18(21), 5809-5814.
72. Smith, W. L.; DeWitt, D. L.; Garavito, R. M. Cyclooxygenases: structural, cellular, and molecular biology. Annu. Rev. Biochem., 2000, 69, 145-182.
73. Marnett, L. J.; Rowlinson, S. W.; Goodwin, D. C.; Kalgutkar, A. S.; Lanzo, C. A. Arachidonic acid oxygenation by COX-1 and COX-2. Mechanisms of catalysis and inhibition. J. Biol. Chem., 1999, 274, 22903-22906.
74. Blobaum, A. L.; Marnett, L. J. Structural and Functional Basis of Cyclooxygenase Inhibition. J. Med. Chem., 2007, 50(7), 1425-1441.
75. Ghodsi, R.; Zarghi, A.; Daraei, B.; Hedayati, M. Design, synthesis and biological evaluation of new 2,3-diarylquinoline derivatives as selective cyclooxygenase-2 inhibitors. Bioorg. Med. Chem., 2010, 18(3), 1029-1033.
76. Zarghi, A.; Ghodsi, R.; Azizi, E.; Daraie, B.; Hedayati, M.; Dadrass, O. G. Synthesis and biological evaluation of new 4-carboxyl quinoline derivatives as cyclooxygenase-2 inhibitors. Bioorg. Med. Chem., 2009, 17(14), 5312-5317.
77. Schwieler, L.; Erhardt, S.; Erhardt, C.; Engberg, G. Prostaglandinmediated control of rat brain kynurenic acid synthesis-opposite actions by COX-1 and COX-2 isoforms. J. Neural Transm., 2005, 112(7), 863-872.
78. Edwards, S. R.; Mather, L. E.; Lin, Y.; Power, I.; Cousins, M. J. Glutamate and kynurenate in the rat central nervous system following treatments with tail ischaemia or diclofenac. J. Pharm. Pharmacol., 2000, 52(1), 59-66.
79. Mazzoni, O.; Esposito, G.; Diurno, M. V.; Brancaccio, D.; Carotenuto, A.; Grieco, P.; Novellino, E.; Filippelli, W. Synthesis and pharmacological evaluation of some 4-oxoquinoline-2-carboxylic acid derivatives as anti-inflammatory and analgesic agents. Arch. Pharm. Chem. Life Sci., 2010, 10, 561-569.
80. Baruah, B.; Dasu, K.; Vaitilingam, B.; Vanguri, A.; Casturi, S. R.; Yeleswarapu, K. R. 1,2-Diaryl-1-ethanone and pyrazolo[4,3-c]quinoline-4-one as novel selective cyclooxygenase-2 inhibitors. Bioorg. Med. Chem. Lett., 2004, 14(2), 445-448.
81. Kaila, N.; Janz, K.; DeBernardo, S.; Bedard, P. W.; Camphausen, R. T.; Tam, S.; Tsao, D.H. H.; Keith Jr., J. C.; Nickerson-Nutter, C.; Shilling, A.; Young-Sciame, R.; Wang, Q. Synthesis and biological evaluation of quinoline salicylic acids as P-Selectin antagonists. J. Med. Chem., 2007, 50(1), 21-39.
82. Robinson, S. D.; Frenette, P. S.; Rayburn, H.; Cummiskey, M.; Ullman-Culleré, M.; Wagner, D. D.; Hynes, R. O. Multiple, targeted deficiencies in selectins reveal a predominant role for Pselectin in leukocyte recruitment. Proc. Natl. Acad. Sci. U.S.A. 1999, 96(20), 11452-11457.
83. Thorlacius, H. Selectins as targets in inflammatory diseases. Curr. Med. Chem. Anti-Inflammatory Anti-Allergy Agents, 2004, 3(1), 31-38.
84. Chen, Y.-L.; Chen, I.-L.; Lu, C.-M.; Tzeng, C.-C.; Tsao, L.-T.; Wang, J.-P. Synthesis and anti-inflammatory evaluation of 4-anilinofuro[2,3-b] quinoline and 4-phenoxyfuro[2,3-b]quinoline derivatives. Part 3. Bioorg. Med. Chem., 2004, 12(2), 387-392.
85. Sun, X.-Y.; Wei, C.-X.; Chai, K.-Y.; Piao, H.-R.; Quan, Z.-S. Synthesis and anti-inflammatory activity evaluation of novel 7-alkoxy 1-amino-4,5- dihydro[1,2,4]triazole[4,3-a]quinolines. Arch. Pharm. Chem. Life Sci., 2008, 341 (5), 288-293.
86. Bekhit, A. A.; El-Sayed, O. A.; Aboulmagd, E.; Park, J. Y. Tetrazolo[ 1,5-a]quinoline as a potential promising new scaffold for the synthesis of novel anti-inflammatory and antibacterial agents. Eur. J. Med. Chem., 2004, 39(3), 249-255.
87. Pearce, A. N.; Chia, E. W.; Berridge, M. V.; Clark, G. R.; Harper, J. L.; Larsen, L.; Maas, E. W.; Page, M. J.; Perry, N. B.; Webb, V. L.; Copp, B. R. Anti-inflammatory thiazine alkaloids isolated from the New Zealand Ascidian Aplidium sp.: Inhibitors of the neutrophil respiratory burst in a model of gouty arthritis. J. Nat. Prod., 2007, 70(6), 936-940.
88. Chia, E. W.; Pearce, A. N.; Berridge, M. V.; Larsen, L.; Perry, N. B.; Sansom, C. E. Godfrey, C. A.; Hanton, L. R.; (Leon) Lu, G.-L.; Walton, M.; Denny, W. A.; Webb, V. L.; Copp, B. R.; Harper, J. L. Synthesis and anti-inflammatory structure-activity relationships of thiazine-quinoline- quinones: Inhibitors of the neutrophil respiratory burst in a model of acute gouty arthritis. Bioorg. Med. Chem., 2008, 16(21), 9432-9442.
89. El-Gazzar, A.-R. B. A.; El-Enanyb, M. M.; Mahmouda, M. N. Synthesis, analgesic, anti-inflammatory, and antimicrobial activity of some novel pyrimido[4,5-b]quinolin-4-ones. Bioorg. Med. Chem., 2008, 16(6), 3261-3273.
90. El-Gazzar, A. B. A.; Hafez, H. N.; Nawwar, G. A. M. New acyclic nucleosides analogues as potential analgesic, antiinflammatory, anti-oxidant and anti-microbial derived from pyrimido[4,5-b]quinolines Eur. J. Med. Chem., 2009, 44(4), 1427-1436.
91. Cooper, N. Phosphodiesterase 4 inhibitors for the treatment of inflammation associated with respiratory disease. PhD thesis, University of Greenwich, U. K. August 2010.
92. Billah, M. M.; Cooper, N.; Minnicozzi, M.; Warneck, J.; Wang, P.; Hey, J. A.; Kreutner, W.; Rizzo, C.A.; Smith, S. R.; Young, S.; Chapman, R. W.; Dyke, H.; Shih, N.-Y.; Piwinski, J. J.; Cuss, F. M.; Montana, J.; Ganguly, A. K.; Egan, R. W. Pharmacology of N-(3,5-Dichloro-1-oxido-4-pyridinyl)-8-methoxy-2- (trifluoromethyl)-5-quinoline carboxamide (SCH351591), a novel, orally active phosphodiesterase 4 inhibitor. J. Pharmacol. Exp. Ther. 2002, 302 (1), 127-137.
93. Losco, P. E.; Evans, E. W.; Barat, S. A.; Blackshear, P. E.; Reyderman, L.; Fine, J. S.; Bober, L. A.; Anthes, J. C.; Mirro, E. J.; Cuss, F. M. The toxicity of SCH351591, a novel phosphodiesterase-4. Tox. Pathol., 2004, 32, 295-308.
94. Available from: http://www.gsk-clinicalstudyregister.com/quicksearch- list.jsp?item=GSK256066&type=Compound&letterrange=G-K&studyType= All&phase=All&population=All&marketing=All.
95. Viljoen, A.; Mncwangi, N.; Vermaak, I. Anti-Inflammatory Iridoids of Botanical Origin. Curr. Med. Chem., 2012, 19(14), 2104-2127.
96. Li, N.G.; Shi, Z.H.; Tang, Y.P.; Wei-Li.; Lian-Yin.; Duan, J.A. Discovery of Selective Small Molecular TACE Inhibitors for the Treatment of Rheumatoid Arthritis. Curr. Med. Chem., 2012, 19(18), 2924-2956.